Aslan Pharmaceuticals Pte. Ltd., of Singapore, reported that data from a phase Ib study of lead candidate, varlitinib, in combination with doublet chemotherapy to treat patients with metastatic solid tumors showed the regimen was safe, well tolerated and showed efficacy signals in cholangiocarcinoma.